智康弘义全球首创新一代靶向CDH3的抗体偶联药物(ADC)获批美国临床 智康弘义——国内首个获批进入临床的WEE1小分子抑制剂SC0191片获批 Ib/II 期临床,拟用于治疗晚期卵巢癌
be less sensitive towards lapatinib when compared with those lines with an epithelial phenotype (mean IC505.84vs2.78,P=0.079). Conversely, we were able to demonstrate inverse correlations between IC50values and the relative expression of CDH1 (r=−0.25,P=0.283), CDH3 (r=−0.60,P=0.007), ...